Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v16-FR Version v3-EN
Language French English
Date Updated 2020-01-30 2019-09-19
Drug Identification Number 02045702 02045702
Brand name TEVA-SUCRALFATE TEVA-SUCRALFATE
Common or Proper name SUCRALFATE SUCRALFATE
Company Name TEVA CANADA LIMITED TEVA CANADA LIMITED
Ingredients SUCRALFATE SUCRALFATE
Strength(s) 1G 1G
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL
Packaging size 500 500
ATC code A02BX A02BX
ATC description DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD) DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD)
Reason for shortage Requirements related to complying with good manufacturing practices. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2019-08-28 2019-08-28
Estimated end date 2020-02-29 2019-10-31
Actual end date 2020-01-29
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments